Alisporivir

DRUG11 trials

Sponsors

Debiopharm International SA, Assistance Publique - Hôpitaux de Paris

Conditions

Chronic PainHepatic InsufficiencyHepatitis CKidney Failure, ChronicLiver DiseaseSARS-CoV-2

Phase 1

Evaluate the Pharmacokinetics, Safety, and Tolerability of Alisporivir in Subjects With Hepatic Impairment Compared to Healthy Subjects

CompletedNCT01860326

Debiopharm International SAHepatic Insufficiency

Start: 2011-03-31End: 2011-09-30Updated: 2016-04-28

Pharmacokinetics and Safety of Alisporivir in Subjects With End Stage Renal Disease on Hemodialysis Compared to Healthy Subjects

CompletedNCT01975337

Debiopharm International SAKidney Failure, Chronic

Start: 2013-08-31End: 2014-02-28Updated: 2016-08-17

Phase 2

Efficacy and Safety of Adding Alisporivir (DEB025) to Peginterferon (IFN) Alfa-2a (Peg-IFN Alfa-2a) and Ribavirin in Chronic HCV Genotype 1 Patients Who Relapsed or Did Not Respond to Previous Treatment

CompletedNCT01183169

Debiopharm International SAHepatitis C

Start: 2010-08-31End: 2013-05-31Updated: 2016-08-25

Efficacy and Safety of Alisporivir Alone or Combined With RBV or PEG in Chronic Hepatitis C Genotype 2 and 3 Treatment-naïve Participants

CompletedNCT01215643

Debiopharm International SAChronic Pain, Hepatitis C

Start: 2010-10-31End: 2012-05-31Updated: 2016-08-30

Alisporivir With RBV in Chronic Hepatitis C Genotype 2 and 3 Participants for Whom Interferon is Not an Option

CompletedNCT02094443

Debiopharm International SAHepatitis C, Liver Disease

Start: 2014-03-31End: 2015-04-30Updated: 2016-10-13

Evaluation of Alisporivir for the Treatment of Hospitalised Patients With Infections Due to SARS-CoV-2 (COVID-19)

CompletedNCT04608214

Assistance Publique - Hôpitaux de ParisSARS-CoV-2

Start: 2021-01-08End: 2022-04-13Updated: 2023-05-11

Phase 3

Efficacy and Safety of Alisporivir Triple Therapy in Chronic Hepatitis C Genotype 1 Treatment-naïve Participants

CompletedNCT01318694

Debiopharm International SAHepatitis C

Start: 2011-03-31End: 2013-08-31Updated: 2016-09-30

Alisporivir (Deb025) and Boceprevir Triple Therapies in African American Participants Not Previously Treated for Chronic Hepatitis C Genotype 1

TerminatedNCT01446250

Debiopharm International SAHepatitis C

Start: 2011-12-31End: 2013-05-31Updated: 2017-01-16

Alisporivir With PEG and RBV in Protease Inhibitor (PI) Treatment Failure Patients With Chronic Hepatitis C

TerminatedNCT01500772

Debiopharm International SAHepatitis C

Start: 2012-03-31End: 2012-05-31Updated: 2016-08-01

Long Term Follow-up Study to Assess Durability of Sustained Virologic Response in Alisporivir-treated Hepatitis C Patients

CompletedNCT02753699

Debiopharm International SAHepatitis C

Start: 2011-12-31End: 2015-05-31Updated: 2016-08-26

Unknown Phase

Pharmacokinetics, Pharmacodynamics and Safety of DEB025 Plus Ribavirin in Chronic Hepatitis C Genotype 2 and 3 Treatment naïve Patients

CompletedNCT01970904

Debiopharm International SAHepatitis C, Liver Disease

Start: 2013-10-31End: 2015-03-31Updated: 2016-04-20